BMY vs PNTG: fair value comparison
Bristol-Myers Squibb Company and The Pennant Group, Inc. · Updated 2026-10-19
BMY currently screens as overvalued while PNTG screens as fairly valued. Within Healthcare, PNTG currently sits closer to the top of our ranking by discount to fair value. BMY carries the stronger quality grade.
| BMY | PNTG | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $59.12 | $41.87 |
| 12-month range | $42.60–$68.09 | $23.75–$42.48 |
| Rank by discount to fair value | #72 of 108 Healthcare | #71 of 108 Healthcare |
| Quality grade | B | F |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · PNTG fair value analysis